IDNA Genomics Public Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	0.51	0.49	0.48	0.49
Revenue Growth	-0.73%	2.95%	-3.01%	-
Cost of Revenue	0.63	0.62	0.35	0.17
Gross Profit	-0.12	-0.13	0.13	0.32
Selling, General & Admin	1.97	2.1	1.67	1.54
Other Operating Expenses	-0.09	-0.09	-0.07	-0.01
Operating Expenses	1.88	2.02	1.61	1.53
Operating Income	-2	-2.15	-1.48	-1.2
Interest Expense	-0.19	-0.2	-0.15	-0.13
Other Non Operating Income (Expenses)	0	-0	-0	-0
EBT Excluding Unusual Items	-2.19	-2.34	-1.63	-1.34
Impairment of Goodwill	-	-	-1.34	-
Asset Writedown	-1.1	-1.1	-	-
Pretax Income	-3.28	-3.44	-2.97	-1.34
Income Tax Expense	0.02	0.03	0.01	0.01
Earnings From Continuing Operations	-3.3	-3.46	-2.97	-1.34
Minority Interest in Earnings	1.16	1.23	0.45	-
Net Income	-2.14	-2.24	-2.52	-1.34
Net Income to Common	-2.14	-2.24	-2.52	-1.34
Net Income Growth	-	-	-	-
Shares Outstanding (Basic)	3	3	3	3
Shares Outstanding (Diluted)	3	3	3	3
Shares Change	-	-	-	-
EPS (Basic)	-0.78	-0.81	-0.91	-0.49
EPS (Diluted)	-0.78	-0.81	-0.91	-0.49
EPS Growth	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Free Cash Flow	-0.95	-0.25	-2.53	-0.01
Free Cash Flow Per Share	-0.34	-0.09	-0.92	-0.01
Gross Margin	-23.75%	-26.36%	27.22%	65.56%
Operating Margin	-393.06%	-436.22%	-309.19%	-244.23%
Profit Margin	-420.44%	-454.68%	-527.75%	-272.77%
Free Cash Flow Margin	-185.78%	-50.83%	-528.51%	-2.62%
EBITDA	-1.97	-1.99	-1.31	-1.12
EBITDA Margin	-	-	-274.54%	-227.85%
D&A For EBITDA	0.03	0.16	0.17	0.08
EBIT	-2	-2.15	-1.48	-1.2
EBIT Margin	-	-	-	-244.23%